Literature DB >> 20041940

The natural history of epilepsy in tuberous sclerosis complex.

Catherine J Chu-Shore1, Philippe Major, Susana Camposano, David Muzykewicz, Elizabeth A Thiele.   

Abstract

BACKGROUND: Although epilepsy affects most patients with tuberous sclerosis complex (TSC), little is known about the natural history of epilepsy in this genetic disease.
METHODS: A retrospective chart review of all patients with TSC seen between January 2002 and October 2008. Charts were reviewed for a history of infantile spasms (IS), seizure other than IS, refractory epilepsy, Lennox-Gastaut syndrome (LGS), anticonvulsant medication use, ages of seizure onset, last seizure, last clinic visit, clinical seizure phenotype(s), cognitive impairment, and genetic mutation.
RESULTS: Two hundred ninety-one patients were included. Among these patients, 37.8% had a history of IS; 85.2% had a history of seizure; 54.1% developed multiple seizure types, not including IS; 63.2% had seizure onset in the first year of life; and 12.1% of adults without a seizure history developed epilepsy. Of epilepsy patients, 62.5% developed refractory epilepsy and 33.5% achieved epilepsy remission; 37.5% of these patients achieved medication freedom. IS was a risk factor for refractory epilepsy (p<0.0001) and LGS (p<0.0001). History of seizure, IS, age at seizure onset, and refractory epilepsy each correlated with poor cognitive outcome (p<0.0001). Epilepsy remission correlated with better cognitive outcome (p<0.0001). TSC2 was a risk factor for IS and epilepsy; patients without an identified mutation were more likely to achieve remission.
CONCLUSION: Most patients with TSC develop epilepsy and most develop multiple seizure types. Onset typically occurs in the first year of life; however, adults remain at risk. Although refractory epilepsy is common, many patients achieve seizure control. Many features of seizure history are predictive of cognitive and epilepsy outcome.

Entities:  

Mesh:

Year:  2009        PMID: 20041940      PMCID: PMC3065368          DOI: 10.1111/j.1528-1167.2009.02474.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  30 in total

Review 1.  Tuberous sclerosis.

Authors:  D W Webb; J P Osborne
Journal:  Arch Dis Child       Date:  1995-06       Impact factor: 3.791

2.  Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs.

Authors:  S L Dabora; S Jozwiak; D N Franz; P S Roberts; A Nieto; J Chung; Y S Choy; M P Reeve; E Thiele; J C Egelhoff; J Kasprzyk-Obara; D Domanska-Pakiela; D J Kwiatkowski
Journal:  Am J Hum Genet       Date:  2000-12-08       Impact factor: 11.025

3.  Usefulness of diagnostic criteria of tuberous sclerosis complex in pediatric patients.

Authors:  S Józwiak; R A Schwartz; C K Janniger; J Bielicka-Cymerman
Journal:  J Child Neurol       Date:  2000-10       Impact factor: 1.987

Review 4.  Infantile spasms in tuberous sclerosis complex.

Authors:  P Curatolo; S Seri; M Verdecchia; R Bombardieri
Journal:  Brain Dev       Date:  2001-11       Impact factor: 1.961

5.  Seizure remission and antiepileptic drug discontinuation in children with tuberous sclerosis complex.

Authors:  Steven P Sparagana; Mauricio R Delgado; Lori L Batchelor; E Steve Roach
Journal:  Arch Neurol       Date:  2003-09

6.  On the incidence of fits and mental retardation in tuberous sclerosis.

Authors:  D W Webb; A E Fryer; J P Osborne
Journal:  J Med Genet       Date:  1991-06       Impact factor: 6.318

7.  Causes of death in patients with tuberous sclerosis.

Authors:  C W Shepherd; M R Gomez; J T Lie; C S Crowson
Journal:  Mayo Clin Proc       Date:  1991-08       Impact factor: 7.616

8.  The tuberous sclerosis syndrome: clinical and EEG studies in 100 children.

Authors:  G Pampiglione; E J Moynahan
Journal:  J Neurol Neurosurg Psychiatry       Date:  1976-07       Impact factor: 10.154

9.  The relation of infantile spasms, tubers, and intelligence in tuberous sclerosis complex.

Authors:  F J K O'Callaghan; T Harris; C Joinson; P Bolton; M Noakes; D Presdee; S Renowden; A Shiell; C N Martyn; J P Osborne
Journal:  Arch Dis Child       Date:  2004-06       Impact factor: 3.791

10.  Morbidity associated with tuberous sclerosis: a population study.

Authors:  D W Webb; A E Fryer; J P Osborne
Journal:  Dev Med Child Neurol       Date:  1996-02       Impact factor: 5.449

View more
  178 in total

Review 1.  mTOR signaling in epilepsy: insights from malformations of cortical development.

Authors:  Peter B Crino
Journal:  Cold Spring Harb Perspect Med       Date:  2015-04-01       Impact factor: 6.915

2.  In search of epilepsy biomarkers in the immature brain: goals, challenges and strategies.

Authors:  Aristea S Galanopoulou; Solomon L Moshé
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 3.  α-[¹¹C]-methyl-L-tryptophan PET for tracer localization of epileptogenic brain regions: clinical studies.

Authors:  Ajay Kumar; Eishi Asano; Harry T Chugani
Journal:  Biomark Med       Date:  2011-10       Impact factor: 2.851

Review 4.  Autism spectrum disorder and epilepsy: Disorders with a shared biology.

Authors:  Bo Hoon Lee; Tristram Smith; Alex R Paciorkowski
Journal:  Epilepsy Behav       Date:  2015-04-19       Impact factor: 2.937

Review 5.  Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

Authors:  Romina Moavero; Caterina Cerminara; Paolo Curatolo
Journal:  Childs Nerv Syst       Date:  2010-04-01       Impact factor: 1.475

Review 6.  Mammalian target of rapamycin (mTOR) activation in focal cortical dysplasia and related focal cortical malformations.

Authors:  Michael Wong
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

7.  Inflammatory mechanisms contribute to the neurological manifestations of tuberous sclerosis complex.

Authors:  Bo Zhang; Jia Zou; Nicholas R Rensing; Meihua Yang; Michael Wong
Journal:  Neurobiol Dis       Date:  2015-05-21       Impact factor: 5.996

8.  Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma.

Authors:  Darcy A Krueger; Marguerite M Care; Karen Agricola; Cindy Tudor; Maxwell Mays; David Neal Franz
Journal:  Neurology       Date:  2013-01-16       Impact factor: 9.910

9.  The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.

Authors:  Bo Zhang; Jia Zou; Lirong Han; Brennan Beeler; Joseph L Friedman; Elizabeth Griffin; Yue-Shan Piao; Nicholas R Rensing; Michael Wong
Journal:  Epilepsia       Date:  2018-08-05       Impact factor: 5.864

Review 10.  Genetic animal models of malformations of cortical development and epilepsy.

Authors:  Michael Wong; Steven N Roper
Journal:  J Neurosci Methods       Date:  2015-04-21       Impact factor: 2.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.